Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047671 · ClinicalTrials.gov registry record · Phase 4
Ethnic Variations in Antidepressant Response
A Phase 4 study of Depression, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
- 3
- Study locations
NCT00047671: Completed Phase 4 study of Depression, sponsored by National Institute of Mental Health (NIMH).
NCT00047671 is a Phase 4 study of Depression that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 400 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (49% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047671, a Phase 4 study of Depression, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
- 3
- Study locations
Study Summary
This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].
Conditions Studied
Interventions
- DRUG Citalopram
Study Locations (3)
California
- Cedars-Sinai Medical Center, Department of Psychiatry, Clinical Trials Unit - Los Angeles
- UCLA/King-Drew - Los Angeles
- Harbor-UCLA Medical Center - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2002-06 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
What the finished NCT00047671 record still lists
NCT00047671 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Citalopram is the first listed.
NCT00047671 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00047671 about?
NCT00047671 is a clinical study titled "Ethnic Variations in Antidepressant Response". This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].
What is the current status of trial NCT00047671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2002-06. Estimated completion is 2006-11.
What conditions does trial NCT00047671 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00047671?
The interventions under investigation include: Citalopram (DRUG).
Who is sponsoring clinical trial NCT00047671?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047671 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00047671's enrollment target sits among peer trials
400 107th of 679 higher than 568 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia